Applied Genetic Technologies is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Co. focuses on the field of ophthalmology, where it has clinical programs in X-linked retinitis pigmentosa and achromatopsia. Co. also has a clinical-stage program in optogenetics, and preclinical programs in central nervous system, ophthalmology, and otology indications. Co. has developed technological capabilities in the design, construction and manufacture of viral vectors using adeno-associated virus technology. The AGTC stock yearly return is shown above.
The yearly return on the AGTC stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AGTC annual return calculation with any dividends reinvested as applicable (on ex-dates).
|